Form 4: Hookipa Pharma CEO Acquires Stock Options
SEC Form 4 Filing
Hookipa Pharma Inc.'s CEO, Jorn Aldag, acquired 971,400 stock options on April 15, 2024, exercisable at $0.76.
Summary
- On April 15, 2024, Jorn Aldag, the CEO of Hookipa Pharma Inc., acquired 971,400 stock options.
- The exercise price for these options is $0.76.
- The options vest over time, with 25% vesting on April 15, 2025, and the remainder vesting in 12 equal quarterly installments thereafter.
- The expiration date for these options is April 15, 2034.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of stock option grants to the CEO, which is a common practice in executive compensation.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for executives to receive stock options as part of their compensation packages.
Stakeholder Impact
- The acquisition of stock options by the CEO could potentially align his interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 04/15/2024 | Date of transaction: CEO acquired 971,400 stock options. |
| 04/15/2025 | 25% of the acquired stock options vest. |
| 04/15/2034 | Expiration date of the stock options. |
| 04/17/2024 | Date of filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.